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Abstract
Background: The emergence of resistance to first line antiretroviral therapy (ART) regimen leads to the need for
more expensive and less tolerable second line drugs. Hence, it is essential to identify and address factors associated
with an increased probability of first line ART regimen failure. The objective of this article is to report on the
predictors of first line ART regimen failure, the detection rate of ART regime failure, and the delay in switching to
second line ART drugs.
Methods: A retrospective cohort study was conducted from 2005 to 2011. All HIV infected children under the age
of 15 who took first line ART for at least six months at the four major hospitals of Addis Ababa, Ethiopia were
included. Data were collected, entered and analyzed using Epi info/ENA version 3.5.1 and SPSS version 16. The Cox
proportional-hazard model was used to assess the predictors of first line ART failure.
Results: Data of 1186 children were analyzed. Five hundred seventy seven (48.8%) were males with a mean age of
6.22 (SD = 3.10) years. Of the 167(14.1%) children who had treatment failure, 70 (5.9%) had only clinical failure, 79
(6.7%) had only immunologic failure, and 18 (1.5%) had both clinical and immunologic failure. Patients who had
height for age in the third percentile or less at initiation of ART were found to have higher probability of ART
treatment failure [Adjusted Hazard Ratio (AHR), 3.25 95% CI, 1.00-10.58]. Patients who were less than three years old
[AHR, 1.85 95% CI, 1.24-2.76], chronic diarrhea after initiation of antiretroviral treatment [AHR, 3.44 95% CI, 1.37-8.62],
ART drug substitution [AHR, 1.70 95% CI, 1.05-2.73] and base line CD4 count below 50 cells/mm3 [AHR, 2.30 95% CI,
1.28-4.14] were also found to be at higher risk of treatment failure. Of all the 167 first line ART failure cases, only 24
(14.4%) were switched to second line ART with a mean delay of 24 (SD= 11.67) months. The remaining 143 (85.6%)
cases were diagnosed to have treatment failure retrospectively by the authors based on their records. Hence, they
were not detected and these patients were not offered second line ARTs.
Conclusions: Having chronic malnutrition, low CD4 at base line, chronic diarrhea after initiation of first line ART,
substitution of ART drugs and age less than 3 years old were found to be independent predictors of first line ART
failure in children. Most of the first line ART failure cases were not detected early and those that were detected
were not switched to second line drugs in a timely fashion. Children with the above risk factors should be closely
monitored for a timely switch to second line highly active anti-retroviral therapy.
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Background
The human immunodeficiency virus (HIV) epidemic
continues to be a major challenge to global health.
According to the 2009 UNAIDS report, about 33.4 mil-
lion people worldwide were living with HIV/AIDS
(LWHA) and of them 2.1 million were children. In 2008
alone, 430 thousand children under the age of 15 were
newly infected with HIV, and 280 thousand children lost
their lives because of acquired immune deficiency syn-
drome (AIDS) [1]. Sub-Saharan Africa continues to be
the region most affected by the pandemic, with nearly
90% of all new childhood HIV infections and approxi-
mately 7 of 10 recorded deaths occurring in this region
[1,2].
In 2006, Ethiopia reported that there were nearly 134
thousand children under the age of 15 years old LWHA
[3]. In 2009, there were 29, 546 pediatric patients “ever
enrolled in HIV care”, and 13,650 were “ever started on
anti-retroviral therapy (ART)” [4]. In 2009, there were
10,361 children who were on first line ART regimens
and 135 children on second line ART regimens [4].
Many studies have reported on the success of highly
active anti retroviral therapy (HAART) in improving
clinical and immunologic outcomes of children [5-9].
However, as the use of HAART increases, the issue of
drug resistance and subsequent treatment failure pre-
senting as one or more of clinical, immunological or
virological ART failure appears as a challenge [10-12].
Clinical failure is defined as the occurrence of new op-
portunistic infections (OIs) or malignancies; failure to
sustain growth rate in a child who had showed an initial
response; or loss of neurodevelopment milestones ex-
cluding cases of inadequate nutrition or tuberculosis
[10-12]. Immunologic failure is a rapid, serial rate of de-
cline to the cut-off values for severe immunodeficiency
state for age or below; or a fall in CD4 by 50% from the
recorded peak in the absence of a concurrent illness
[10,12]. Generally, treatment failure is different from im-
mune reconstitution inflammatory syndrome (IRIS). IRIS
is a paradoxical clinical deterioration that occurs even
when the immune system begins to improve, while no
immunologic improvement occurs in treatment failure
[10,13].
Factors associated with ART failure may include socio-
demographic factors (e.g. age, gender, being an orphan),
baseline clinical factors (e.g. high pre-treatment viral
load, low pre-treatment CD4 count, prior World Health
Organization (WHO) stage), drug-drug interactions
(between the ART and concomitantly administered
drugs), drug side-effects, drug toxicity or inadequate
adherence to treatment [14-22].
In an Ethiopian university hospital, among children on
first line ART, clinical treatment failure and immuno-
logic treatment failure were diagnosed in 6.2% and
11.5% respectively [22]. The presence of chronic gastro-
enteritis or the appearance of a new opportunistic infec-
tion after starting treatment was associated with
immunologic treatment failure [22]. Deaths that oc-
curred within the first three months of therapy were
associated with higher rates of default, treatment failure,
severe drug toxicity and regimen changes [22].
ART failure is not a common diagnosis in most centers
in Ethiopia. Very few patients among the needy are started
on second line ART regimens. Previous studies have eval-
uated the patterns associated with switching from first line
ART regimes to second line ART regimes; however, studies
that evaluate the factors associated with first line ART re-
gime failures in limited resource settings like Ethiopia and
Africa at large are scarce. The objective of this article is to
report on the predictors of first line ART regime failure,
the detection rate of ART regime failure, and the delay in
switching to second line ART drugs.
Methods
Setting
We conducted a retrospective cohort study of children
with HIV/AIDS in Addis Ababa, the capital of Ethiopia.
The city area is 450 square kilometers with an esti-
mated population of 2.7 million. The four major public
pediatric referral hospitals in the city with strong
pediatric HIV/AIDS care and treatment centers were
selected for the study, and they include Tikur Anbessa,
Yekatit 12, Zewditu Memorial and ALERT hospital. All of
the children at the four ART centers who had been
started on first line ART drugs based on the national
guideline by professionals working at the respective
center were included. Ethical approval was obtained from
the institutional review board of the Addis Ababa health
Beuro and each hospital in the study. Confidentiality was
assured by making the questionnaires anonymous [10].
Sample
We used retrospective data of 1186 children under
15 years old who were on ART regimes between March
2005 and March 2011 at the ART centers of the four
major hospitals. Children seen at these centers were fol-
lowed based on the national guidelines which recom-
mends that children are evaluated two weeks after
initiation of ART, every month for the next two months,
and every three months afterwards. Children who had a
minimum of two follow-up visits with at least one visit
six months post initiation of ART were included in the
sample. Children who took ART only for prevention of
mother to child transmission (PMTCT) were excluded.
Data/measures
We abstracted data from the patients’ medical records
to a structured data retrieval form. These records
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included: clients’ age, gender, weight, height, duration of
follow up, clinical and laboratory data (WHO stage, op-
portunistic infections, CD4 count and white cell count),
the ART regimen and prophylaxis (Co-trimoxazole or
Isoniazid), and adherence were all recorded on a struc-
tured data retrieval form. The data were collected from
the records starting from the time of ART initiation and
every six month afterwards. Because growth was not
routinely plotted on the growth chart by the profes-
sionals working at the centers, we used the recorded
weight and height to plot growth for each child every six
months.
We used the standard definition of clinical failure
defined as occurrences of new opportunistic infections
(OIs) or malignancies or failure to sustain growth rate in
a child who had showed response initially or loss of neu-
rodevelopmental milestones excluding other causes in-
cluding inadequate nutrition and tuberculosis [10-12].
Growth failure was diagnosed when a child’s growth tra-
jectory (weight-for-age, height for age and/or weight for
height) decreased by two percentile curves or when it
was below the third percentile for age in the standardized
curves of WHO. In the current study, growth failure was
taken as a sign of ART failure when the altered growth
stayed for more than six months at follow up. Immuno-
logic failure was defined at follow up according to the na-
tional guideline. Virologic criteria were not used because
of the complexity of defining ART failure in children
using viral load and the unavailability of regular virologic
tests in Ethiopia [10]. Patients with opportunistic infections
were differentiated from those patients having IRS based
on the pattern of their CD4 counts [10].
In this cohort, the time to detection of treatment failure
indicates the time between ART initiation and detection of
failure of first line ART (clinical or immunologic failure).
Time to switch to second line ART regimens represents
the time between detection of first line treatment failure
and the time of initiation of second line drugs. Adherence
was defined as optimal if pill count or self report was
greater than or equal to 95% and sub optimal if pill count
or self report was less than 95%. IRIS was noted when op-
portunistic infections occurred during the first several
months of initiation of ART in the presence of immune
recovery [10,13].
Statistical analysis
The data were entered and analyzed using SPSS version
16. Z-scores and percentiles of anthropometric values
were calculated using Epi-Info/ENA version 3.5.1 (CDC,
Atlanta, Georgia, and USA, 2008) Descriptive statistics
including counts, percentages, medians, ranges, means,
and standard deviations were calculated. Association be-
tween the outcome and the independent variables was
taken as significant at P < 0.05. First-line ART failure was
further described by subcategories of demographic and
clinical characteristics. Independent variables that were
significantly associated with first-line ART failure in bi-
variate analysis were further examined in multivariate
analysis. The Cox proportional-hazards model was used
to assess the predictors associated with treatment failure.
Those factors with P < 0.2 in the bi-variate model were
included in the multivariate analysis. Kaplan-Meier sur-
vival methods were used to estimate the probability of
treatment failure. Log rank test was employed to com-
pare survival curves.
Results
From the 1,186 children on first line HAART, 608
(51.2%) were female (Table 1). Four hundred four
(34.1%), 315 (26.6%), 252 (21.2%) and 215(18.1%) had a
follow up at Tikur Anbessa hospital, Zewditu hospital,
Yekatit 12 hospital and ALERT hospital respectively.
The mean age at initiation of ART was 6.22 (SD= 3.10)
years and ranged from 2- to 14 years old. The mean fol-
low up period after ART initiation in the current study
was 37±17 months, with minimum 6 months to maximum
of 74 months.
PMTCT service was very low; only 2.4% of the children
received the service (0.8% received only Nevirapine
(NVP) and 1.6% received NVP and Zidovudin (ZDV).
ART initiation occurred due to advanced World Health
Organization (WHO) clinical staging in 210 (17.7%)
patients, low CD4 count in 248 (20.9%) patients and
both WHO and immunologic criteria in 719 (60.6%)
patients. Infants with diagnosed HIV/AIDS accounted
for 9 (0.8%) of the patients which is a criteria for initiation
by itself. The regimen type initiated at base line was NVP
based in 688 (58%) patients and Efavirenz (EFV) based in
467 (39.3%) patients (Table 2).
A large number of children were malnourished at base
line with 14.5%, 27.9% and 2.4% of children falling at or
below the third percentile for weight for age, height for
age and weight for height respectively. At ART initiation,
450 (37.9%) of the children were found to be in severe
age adjusted immunodeficiency state based on CD4 per-
centage for those less than 5 years of age or CD4 count
for those above 5 years of age. The CD4 count was less
than 50 cells/mm3 in 80 (6.7%) of all children. The mean
CD4 count for the whole cohort at initiation of ART was
300 cells/mm3 (SD=271 cells/mm3). Though a large num-
ber of children had severe immunodeficiency at base line,
the mean increment of CD4 count was remarkable until
12 months after initiation of ART (P<0.0001). CD4 count
continued to increase slowly until 36 months after initiation
of ART though not statistically significant (P=0.48). CD4
count started to decline after 42 months of initiation of
ART. The mean CD4 count was 685 cells/mm3 (SD =
560cells/mm3), 741 cells/mm3 (SD = 373 cells/mm3),
Bacha et al. BMC Infectious Diseases 2012, 12:197 Page 3 of 8
http://www.biomedcentral.com/1471-2334/12/197
772 cells/mm3 (SD=423 cells/mm3) and 580 cells/mm3
(SD=421cells/mm3) at one year, two years, three years
and five years after initiation of ART respectively.
Forty one (3.5%) children had opportunistic infections
after the initiation of ART; the mean time for onset of
opportunistic infections after initiation of ART was
20.8 ±15.9 months with a range of 2–62 months. The
most common opportunistic infections were disseminated
tuberculosis (TB) (3%), pneumocystis carinii pneumonia
(PCP) (0.2%), recurrent intractable oral thrush (0.2%), and
recurrent severe pneumonia (0.1%). The overall adherence
rate was reported to be optimal; with no episode of sub-
optimal adherence in 98.4% and two or more episodes of
suboptimal adherence in only 1.6% of the patients.
Anti-retroviral drug substitution occurred for 105 (8.9%)
patients. Substitution was necessary because of toxicity for
94 (7.9%) patients, and concomitant TB treatment for 7
(0.6%) patients. Toxicity was more common in the 4c
Table 1 Baseline characteristics of children on HAART€




-≤ 11 months 46(3.9 )
-11 to 34 169 (14.2)
-34 to 59 212 (17.9)




Duration of Follow up
-Less than one year 265(22.3)
-One to two years 270(22.8)
-Two to three years 248(20.9)
-Three to four years 225(19.0)























-Below 3rd centile 172(14.5)
->3rd centile < 97th centile 192(16.2)
-Above 97th centile 44(3.7)
-Unknown 778 (65.6)
Height- for- Age
-Below 3rd centile 327(27.6)
->3rd centile < 97th centile 763(6.3)
Table 1 Baseline characteristics of children on HAART€
Treated in four ART# Centers in Addis Ababa, Ethiopia
followed from 2005–2011 (Continued)
-Above 97th centile 81(6.8)
-Unknown 15(1.3)
Weight- for –Height
-Below 3rd centile 105(8.9)
->3rd centile < 97th centile 245(20.7)
-Above 97th centile 707(59.6)
-Unknown 129(10.9)
Regimen started at initiation of ART
-4a (D4T + 3TC+NVP) 388(32.7)
-4b(D4T+ 3TC+ EFV) 106(8.9)
-4c(ZDV+ 3TC+NVP) 300(25.3)












Chronic Diarrhea after initiation
-Yes 16 (1.3)
-None 1170(98.7)
€ Highly Active Antiretroviral Therapy # Antiretroviral Therapy $ Level of
immunosupression is based on the Ethiopian National ART guideline [10].
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(ZDV+3TC+NVP) regimen. Among the 94 children with
toxicity: 33 (35.1%), 29 (31.0%), 20 (21.3%) and 12(12.6%)
were on 4c (ZDV+3TC+NVP), 4a (D4T+3TC+NVP),
4b (D4T+3TC+EFV) and 4d (ZDV+3TC+EFV) regi-
mens respectively. The most common recorded side
effects of drug toxicity was anemia; 21(22.3%), followed by
skin rash; 13 (13.8%), hepatotoxicity; 10/ (10.6%), lipody-
strophy; 6 (6.4%), neuropathy; 4 (4.3%), night terror;
1(1.1%), and severe nausea 1 (1.1%).
Patients who had height for age less than the 3rd per-
centile at initiation of HAART were found to have a
higher probability of treatment failure [AHR, 3.25 95% CI,
1.00-10.58] (Table 3). Compared to patients with base line
CD4 count above 50 cells/mm3, those below 50 cells/mm3
had higher probability of treatment failure [AHR, 2.30
95% CI, 1.28-4.14]. Similarly the presence of chronic diar-
rhea after initiation of ART [AHR, 3.44 95% CI, 1.37-8.62]
and ART drug substitution [AHR, 1.70 95% CI, 1.05-2.73]
were also found to be a risk of treatment failure.
There were 167 (14.1%) children with HIV/AIDS who
had evidence of first line ART failure of which 70 (5.9%)
had clinical treatment failure, 79(6.7%) immunologic failure
and 18 (1.5%) developed both immunologic and clinical
failure. Out of all children with first line ART failure,
only 24 (14.4%) were identified at the four ART centers.
The mean time of detection of treatment failure was
19.7 months (SD = 14 months) and the mean time to
switch to second line ART regimen, for those switched,
was 24 months (SD= 11.67 months).
Discussion
The current study found that in patients with treatment
failure, clinical failure was the most common followed
by immunologic failure with only a small proportion
having both clinical and immunologic failure. There
was a striking delay in the detection of ART failure.
Only 24 (14.4%) patients were labeled as having treat-
ment failure in all the ART centers and were switched
Table 2 Sociodemographics as predictors of first line ART failure in children with HIV/AIDS¥ Treated in Four
ART3Centers in Addis Ababa, Ethiopia followed from 2005-2011
Covariate Treatment failure Treatment success Crude hazard risk (95 CI**) Adjusted hazard risk (95 CI**)
Age
-< 36 months 46(20.8) 175(79.2) 1.87(1.26-2.76) 1.85(1.24-2.76)
-36-60 months 28(13.3) 183(86.7) 1.09(0.69-1.71) 1.09(0.69-1.72)
->60 months 93(12.3) 661(87.7) 1 1
Gender
-Female 96(15.8) 512(84.2) 1.34(0.96-1.86) 1.30(0.91-1.87)
-Male 71(12.3) 506(87.7) 1 1
Primary Care Taker
-Parent (single/both) 119(14.5) 701(85.5) 1.13(0.78-1.61)
-Non-parent 48(13) 318(87) 1
Care taker HIV sero-status
-Reactive 112(14.5) 661(85.5) 1.12(0.78-1.62)
-Unknown 47(13.1) 311(86.9) 1.13(0.50-2.53)
-Negative 8(14.5) 47(85.5) 1
PMTCT Service
-Present 3(12.5) 21(87.5) 0.93(0.27-3.25)
-None 119(14.4) 705(85.6) 1.10(0.76-1.59)
-Unknown 45(13.3) 293(86.7) 1
Infant ART prophylaxis
-Yes 5(18) 23(82) 1.97(0.67-5.81) 1.43(0.47-4.31)
-None 144(14.7) 833(85.3) 1.57(0.93-2.63) 1.56(0.93-2.63)
-Unknown 18(10) 163(90) 1 1
Disclosure£
-Disclosed 41(13.2) 270(86.8) 1.04(0.69-1.57)
Not disclosed 73(12.7) 501(87.3) 1
**Confidence interval £ Is telling children about their HIV status and was done for children older than 8 years ¥ Human Immunodeficiency virus/ Acquired
Immunodeficiency syndrome 3 Antiretroviral therapy.
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to second line therapy. Our finding of 167 first line
ART failures in the four hospitals is greater than the
135 pediatric patients that were identified by the na-
tional report and put on second line drugs following
first line ART failure [3,4]. Our findings demonstrates
that a significant number of pediatric treatments fail-
ures are not identified and/or not switched to second
line ART.
The current study shows that children under three
years old, chronic malnutrition, low CD4 count at ART
initiation, chronic diarrhea after ART initiation and ART
drug substitution are independent predictors of first
line ART failure. Similarly, studies elsewhere showed
that younger age is a predictor of virologic failure
[21,23-25]. Chronic malnutrition was also shown to be a
predictor of treatment failure previously in Ethiopian
Table 3 Clinical and treatment data of children with HIV/AIDS α Treated in four ART¥ Centers in Addis Ababa, Ethiopia
followed from 2005-2011
Covariate Treatment failure (%) Treatment success (%) Crude hazard risk (95 CI**) Adjusted hazard risk (95 CI**)
Weight for Age
-Below 3rd centile€ 52(30.2) 120(69.8) 2.74(1.09-6.89) 0.54(0.13-2.25)
>3rd < 97th centile 107(55.7) 85(44.3) 0.79(0.32-1.92) 0.41(0.11-1.55)
Above 97th centile 6(13.6) 38(86.4) 1 1
Height for Age
Below 3rd centile 88(27) 239(63) 2.61(1.29-5.29) 3.25(1.00-10.58)
>3rd < 97th centile 66(8.7) 697(91.3) 0.67(0.33-1.37) 1.05(0.33-3.33)
Above 97th centile 10(22.2) 71(77.8) 1 1
Weight for Height
Below 3rd centile 15(14.3) 90(85.7) 1.10(0.61-1.98)
>3rd < 97th centile 41(16.7) 204(83.3) 1.33(0.89-1.98)
Above 97th centile 93(13.2) 614(86.8) 1
WHO Clinical stage
Stages 1 or 2 58(12.7) 400(87.3) 0.84(0.59-1.18)
Stage 3 or 4 107(14.8) 617(85.2) 1
Adherence to HAART
Optimal 162(14) 1006(86) 0.41(0.15-1.19)
Suboptimal 5(27.3) 13(72.7) 1
Initial HAART Regimen
PI based £ 10(32.3) 21(67.7) 3.03(1.40-6.55) 1.05(0.33-3.89)
NNRTI +NRTI 157(13.6) 998(86.4) 1 1
HAART drug substitution
Yes 29(23.6) 94(76.4) 2.07(1.31-3.25) 1.695(1.053-2.728)
None 138(13) 925(87) 1 1
HAART Dosing preparation
Fixed 9(17.6) 42(82.4) 1.18(0.56-2.49)
Separate 109(15.4) 600(84.6) 1
CD4 Count at initiation
(cells/mm3)
<50 19(23.8) 61(76.2) 2.39(1.38-4.15) 2.30(1.28-4.14)
≥50 112(11.5) 859(88.5) 1 1
Chronic Diarrhea after
initiation of ART¥
Yes 6(37.5) 10 (62.5) 3.76(1.35-1.50) 3.44 (1.37-8.62)
None 161(13.8) 1009(86.2) 1 1
**Confidence interval £-Started for infants who took prophylaxis; α Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome ¥ Antiretroviral therapy € Percentile.
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and Singapore [22,25]. Likewise, an Ethiopian study in
Jimma showed that chronic diarrhea before initiation of
ART was predictive of treatment failure [22]. Our find-
ing of a higher risk of first line ART failure in children
who had ART drug substitution in the current study is
consistent with a study conducted in Malawi [17].
Some possible mechanisms by which the above predic-
tors could affect treatment include difficulty of drug ad-
ministration in those below three years of age, the high
prevalence of underlying malnutrition which increases
the risk of infection, and chronic diarrhea which in turn
decrease drug absorption and impair metabolism. The
children with low CD4 count at initiation could have an
increased risk of opportunistic infections which further
impairs the positive effects of the ART.
Only a few patients among those who actually had
treatment failure were detected at the ART centers. The
mean duration of treatment failure on first line ART and
the mean duration from detection of treatment failure to
switch to second line ART were longer in our study than
the studies in Malawi [17] and South Africa [19]. One
possible reason for the lack of timely detection of ART
failure in the current study is the poor recording of
growth parameters (through plotting) which was not
regularly done in all the ART centers included in the
study. The rate of development of OIs in the current
study is less than that reported in Jimma [22]; but higher
than the Cambodian [26] and the United States perinatal
AIDS collaborative transmission studies [8].
Only 2.4% of the studied children received drugs for
infant prophylaxis, despite the currently improving rate
of institutional deliveries where PMTCT services are
available. In urban areas (including where this study was
conducted), the health facility delivery based on the re-
cent national data is nearly 50% [27]. Thus, most of
these HIV infections could have been prevented if these
children received PMTCT services.
Adherence to ART regimens was not a statistically sig-
nificant predictor of treatment failure in this study. This
could be due to the high self-reported adherence rate in
the current study which made comparison between the
groups difficult. The adherence rate in the current study
is higher than a cross-sectional study done in the same
region [28] which could be explained by the retrospect-
ive nature of the current study.
The retrospective nature of this study is a limitation
due to incompleteness of the records. The temporal rela-
tion between CD4 count determinations and concurrent
illnesses was sometimes difficult to determine due to the
retrospective nature of the study. Deaths, dropouts,
and transfer patients were not included and this could
have biased our estimates. Although children who had
growth failure that persisted for 6 months were included
as treatment failure cases, it was unclear whether
nutritional therapy was given adequately which would
have influenced existence of treatment failure. Finally,
the lack of viral load to diagnose treatment failure is the
other limitation.
Conclusions
In conclusion, children under 3 years old, chronic mal-
nutrition at ART initiation, chronic diarrhea after the
start of ART, drug substitution during the course of
ART, and having CD4 count less than 50 at base line
were independent predictors of increased risk of treat-
ment failure. The majority of patients with treatment
failure were not diagnosed with treatment failure in a
timely fashion, and there was a significant delay in
switching to second line drugs even after treatment fail-
ure to first line drugs was identified. Hence, prevention
and treatment of malnutrition in this group of children
should be part of the care and treatment they receive as
a part of their HIV treatment. A regular follow up of
these children with growth parameters (including regular
plotting of weight and height) should also be a part of
the routine follow-up at all ART centers. Early initiation
of second line drugs in case of first line treatment failure
should occur in a more timely manner at these centers.
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